DIABETIC MACULAR OEDEMA

A randomised study involving 111 eyes of 105 patients with diabetic macular oedema showed that, compared with baseline values, visual acuity improved significantly more at three and six months among patients receiving triamcinolone alone or in combination with bevacizumab than in eyes receiving bevacizumab alone. All three treatments produce significant reductions in central macular thickness throughout follow-up, with greater reductions during the first months of therapy in the triamcinolone groups. However, by 12 months the groups had statistically similar results in terms of both macular thickness and visual acuity

(Lim et al, Ophthalmologica 2012; 227: 00-106).